| Product No | EMEA/H/C/003912 |
|---|---|
| Brand Name | Cinqaero |
| Nonproprietary Name | reslizumab |
| API | Reslizumab |
| ATC Code | R03DX08 |
| Indications | Cinqaero is indicated as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment. |
| Orphan Drug | no |
| Generics | no |
| Marketing Authorization Holder | Teva B.V. |
| Status | Authorised(授权) |
| Authorization Date | 2016-08-15 |
| Version | 10 |
| Condition Approval | no |
| Exceptions | no |
| Biosimilar | no |
| Details | 查看 (公众评估报告、授权细节、产品规格/剂型、标签、历史评估信息) |
Extended Information